 |
 |
 |
 |
|
|||||||||||
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
Portfolio
Individual partners or the partner team is the co-founder of the following companies:
APIM Therapeutics AS Incorporated in 2009, APIM Therapeutics AS is a spin out of the Norwegian University of Science and Technology (NTNU), Department of Cancer Research and Molecular Medicine in Trondheim, Norway. Based on a novel therapeutic approach targeting DNA repair and cell cycle control, APIM Therapeutics AS develops novel co-drugs with the potential to improve safety and efficacy of many current chemotherapeutic treatments for the benefit of cancer patients. |
.jpg) |
Regenesance BV - -www.regenesance.com Regenesance is a 2009 spin-out of the Academic Medical Center (AMC) in Amsterdam, the Netherlands. Based on a novel therapeutic intervention point, the Company is developing new compounds that may reduce nervous system injury in patients. One compound (RGS1102) significantly enhances nerve function in an animal model of acute nerve damage. Preliminary results in animals with another compound (RGS2064) suggest it may reduce nerve damage after traumatic brain injury (TBI). |
 |
Avexxin AS-www.avexxin.com Avexxin is a 2005 spin-out from research at the Norwegian University of Science and Technology and Oslo University. Avexxin is a pharmaceutical company focused on development of novel small molecule therapeutics for patients with chronic inflammatory conditions. Avexxin's lead compound (AVX001) is targeted at psoriasis and other chronic dermatological disorders. Clinical trial is expected to commence late 2010. Avexxin also has development programs directed at rheumatoid arthritis and glomerulonephritis. |
 |
Exiqon A/S – www.exiqon.com Listed in 2007 on the Nasdac OMX stock exchange in Copenhagen, Exiqon operates in two business areas: life sciences and cancer diagnostics. Exiqon is the home of LNA™ based tools for small RNA research and in diagnostics Exiqon is a market leader in the field of in vitro treatment selection testing for cancer. Exiqon performs innovative genomic research aimed at rapidly identifying new cancer diagnostics to improve the outcome of cancer patients. |
 |
Santaris Pharma A/S – www.santaris.com Santaris Pharma A/S, Denmark and US, is an international clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies. The Company's proprietary Locked Nucleic Acid (LNA) Drug Platform, in combination with its highly specialized and targeted drug development capabilities, offers potential partners pre-screened drug candidates for commercial consideration across a multitude of disease states. Santaris Pharma A/S research and development activities focus on infectious diseases and metabolic disorders while partnerships with major pharmaceutical companies include a range of therapeutic areas including cancer, rare genetic disorders and inflammatory diseases. Santaris Pharma A/S, founded in 2003, is privately-held and headquartered in Denmark with operations in the US. As part of its broad patent estate, the Company holds exclusive worldwide rights to all therapeutic uses of LNAs. The Company has strategic partnerships with Enzon Pharmaceuticals, GlaxoSmithKline, Wyeth Pharmaceuticals (now part of Pfizer) and Shire plc. |
 |